Skip to main content
SpringerLink
Log in

Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma

  • Research Articles
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

Treatment of high-grade osteosarcoma remains a challenge. The prognostic significance of the pre-treatment serum lactate dehydrogenase (LDH) level is currently controversial.

Patients and methods

We reviewed records from all patients diagnosed with conventional high-grade osteosarcoma at our institution over a 25-year period and analysed the prognostic significance of LDH in high-grade localised extremity osteosarcomas treated with chemotherapy.

Results

Between June 1977 and March 2003, 66 patients for whom follow-up was available were diagnosed with localised high-grade extremity osteosarcoma and treated with chemotherapy. The median age was 15 years, with only 3% older than 40 years, and the median follow-up was 100 months. The median progression-free survival (PFS) was 67 months and the median overall survival (OS) was 113 months. The absence of a response to chemotherapy was correlated with a trend toward lower PFS and OS. High serum pre-treatment LDH level was associated in multivariate analyses with a poorer prognosis for both PFS (HR=8.623, 95%CI: 1.71–43.37; p=0.009) and for OS (HR=9.38; 95%CI: 1.73–50.74; p=0.009).

Conclusion

In this series, the pre-treatment serum LDH level had an independent prognostic value for both PFS and OS in patients with high-grade localised extremity osteosarcoma. This measurement should be included in a large prospective prognostic series.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stillera CA, Bielack SS, Jundt G, Steliarova-Fouchere E (2006) Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 42:2124–2135

    Google Scholar 

  2. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  3. Dahlin DC (1978) Bone tumors: general aspects and data on 6221 cases, 3rd Edn. Charles C Thomas, Springfield, IL

    Google Scholar 

  4. Lichtenstein L (1977) Bone tumors, 5th Edn. Mosby, St Louis, MO

    Google Scholar 

  5. Jaffe HL (1958) Tumors and tumorous conditions of the bone and joints. Lea & Febiger, Philadelphia

    Google Scholar 

  6. Malawer MM, Link MP, Donaldson SS (2004) Sarcomas of bone. Cancer, principles and practice of oncology, 6th Edn. Lippincott Williams and Wilkins, Philadephia, PA pp 1981–1995

    Google Scholar 

  7. Weingard DN, Rosenberg SA (1978) Early lymphatic spread of osteogenic and soft tissue sarcomas. Surgery 84:231–240

    Google Scholar 

  8. Enneking WF, Spanier SS, Goodman MA (1980) A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 153:106–115

    PubMed  Google Scholar 

  9. Marcove RC, Rosen G (1980) En bloc resection for osteogenic sarcoma. Cancer 45:3040–3044

    Article  PubMed  CAS  Google Scholar 

  10. Malawer MM (1983) Distal femoral osteogenic sarcoma, principles of soft tissue resection and reconstruction in conjunction with prosthetic replacement (adjuvant surgery). In: Chao EYS (ed.) Design and application of tumor prosthesis for bone and joint reconstruction. Thieme-Stratton, New York, pp 297–308

    Google Scholar 

  11. Enneking WF, Dunham WK (1978) Resection and reconstruction for primary neoplasms involving the innominate bone. J Bone Joint Surg Am 60: 731–746

    PubMed  CAS  Google Scholar 

  12. Rosen G, Marcove RC, Caparros B et al (1979) Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed survey. Cancer 43:2163–2177

    CAS  Google Scholar 

  13. Muggia F, Catani R, Lee YJ et al (1979) Factors responsible for therapeutic success in osteosarcoma. In: Jones S, Salmon S (eds) Adjuvant therapy for cancer, 2nd Edn. Grune & Stratton, New York

    Google Scholar 

  14. Cortes EP, Holland JP (1981) Adjuvant therapy for primary osteogenic sarcoma. Surg Clin North Am 61:1391–1398

    PubMed  CAS  Google Scholar 

  15. Link MP (1986) Adjuvant therapy in the treatment of osteosarcoma. In: DeVita VT, Hellman S, Rosenverg SA (eds) Important advances in oncology. JB Lippincott, Philadelphia, pp 193–194

    Google Scholar 

  16. Link MP, Goorin AM, Miser AW et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600–1605

    PubMed  CAS  Google Scholar 

  17. Eilber F, Guiliano A, Eckardt J et al (1987) Adjuvant chemotherapy for osteosarcoma. a randomized prospective trial. J Clin Oncol 5:21–26

    PubMed  CAS  Google Scholar 

  18. Rosen G, Caparrol B, Huvos AC et al (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based upon the response of the primary tumor to preoperative cancer. Cancer 49:1221–1230

    Article  PubMed  CAS  Google Scholar 

  19. Ferrari S, Smeland S, Mercuri M et al (2005) Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23:8845–8852

    Article  PubMed  Google Scholar 

  20. Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790

    Article  PubMed  Google Scholar 

  21. Ger LP, Wang JW, Lin CC, Wang J (1993) Prognostic factors in 43 cases of osteosarcoma. J Formos Med Ass 92:962–968

    CAS  Google Scholar 

  22. Lopez Aguilar E, Rivera Márquez H, Cerecedo Díaz F et al (1996) Láctico dehidrogenasa como factor pronóstico en el desarrollo de enfermedad pulmonar metastásica en pacientes con osteosarcoma. Gac Med Mex 132:363

    PubMed  CAS  Google Scholar 

  23. Pochanugool L, Subhadharophandou T, Danachai M et al (1997) Prognostic factors among 130 patients with osteosarcoma. Clin Orthop Relat Res 345:206–214

    Article  PubMed  Google Scholar 

  24. Goorin AM, Schwartzentruber DJ, Devidas M et al (2003) Presurgical chemotherapy with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group study POG-8651. J Clin Oncol 21:1574–1580

    Article  PubMed  CAS  Google Scholar 

  25. Bacci G, Ferrari S, Sangiorgi L et al (1994) Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. J Chemother 6:204–210

    PubMed  CAS  Google Scholar 

  26. Bacci G, Longhi A, Ferrari S et al (2004) Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori 90:478–484

    PubMed  Google Scholar 

  27. Meyers PA, Heller G, Healey J et al (1992) Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10:5–15

    PubMed  CAS  Google Scholar 

  28. Rosen G, Murphy ML, Huvos AG et al (1976) Chemotherapy, en bloc resection and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37:1–11

    Article  PubMed  CAS  Google Scholar 

  29. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  30. Mantel M (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170

    PubMed  CAS  Google Scholar 

  31. Cox DR (1972) Regression models and life-tables. J R Stat Soc 34:187–220

    Google Scholar 

  32. Walenta S, Mueller-Klieser WF (2004) Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 14:267–274

    Article  PubMed  Google Scholar 

  33. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1990) Determinants of improved outcome in small-cell lung cancer: an analysis of the 2580 patient Southwest Oncology Group database. J Clin Oncol 9:1563–1574

    Google Scholar 

  34. Tas F, Aykan F, Alici S et al (2001) Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 24:547–550

    Article  PubMed  CAS  Google Scholar 

  35. Kemeny N, Braun DW (1983) Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med 74:786–794

    CAS  Google Scholar 

  36. Smaletz O, Scher HI, Small EJ et al (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20:3972–3982

    Article  PubMed  Google Scholar 

  37. Garcia R, Hernandez JM, Caballero MD et al (1993) Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease. Br J Cancer 68:1227–1231

    PubMed  CAS  Google Scholar 

  38. Bacci G, Ferrari S, Longhi A et al (1999) Prognostic significance of serum LDH in Ewing’s sarcoma of bone. Oncol Rep 6:807–811

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, “12 de Octubre” University Hospital, Madrid, Spain

    Enrique González-Billalabeitia, Ricardo Hitt, Hernán Cortés-Funes & E. González-Billalabeitia

  2. Department of Paediatrics, “12 de Octubre” University Hospital, Madrid, Spain

    Jesús Fernández

  3. Department of Internal Medicine, “12 de Octubre” University Hospital, Madrid, Spain

    Rafael Enríquez de Salamanca

  4. Department of Pathology, “12 de Octubre” University Hospital, Madrid, Spain

    Esther Conde & Francisco Martínez-Tello

  5. Haematology and Oncology Department, Hospital General Universitario Morales Meseguer, C/Marqués de los Vélez, s/n, ES-30008, Murcia, Spain

    E. González-Billalabeitia

Authors
  1. Enrique González-Billalabeitia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ricardo Hitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jesús Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Esther Conde
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francisco Martínez-Tello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rafael Enríquez de Salamanca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hernán Cortés-Funes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. González-Billalabeitia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. González-Billalabeitia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

González-Billalabeitia, E., Hitt, R., Fernández, J. et al. Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma. Clin Transl Oncol 11, 479–483 (2009). https://doi.org/10.1007/s12094-009-0388-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-009-0388-9

Keywords

Search

Navigation